Hippo Pathway Effector Yap Is an Ovarian Cancer Oncogene

Chad A. Hall1, Runsheng Wang2, Jiangyong Miao6, Esther Oliva6, Xiaoyun Shen2, Thomas Wheeler2,3, Susan G. Hilsenbeck3,4, Sandra Orsulic6, and Scott Goode1,2,3,5

Abstract

The Hippo pathway regulates organ size and tumorigenesis in Drosophila and mammals and is altered in a variety of human cancers, yet it remains unclear if the Hippo pathway is of prognostic significance to cancer patients. Here we show that the key targets of Hippo signaling, transcriptional coactivators Yki and Yap, play a conserved role in promoting ovarian cancer in flies and humans, respectively. Whereas studies linking Yap to cancer in other tissues have focused on overall Yap levels, we show for the first time that subcellular levels of Yap show an exceptionally strong association with poor patient survival. Specifically, high levels of nuclear Yap (nYap), or low levels of cytoplasmic phosphorylated Yap (cpYap), associated with poor survival from ovarian cancer. Patients with both high nYap and low cpYap had ~50% lower 5-year survival, and this combination is an independent prognostic marker for survival, with an exceptionally high hazard ratio of 7.8. We find that Yap2 is the predominantly expressed Yap isoform in both the ovarian surface epithelium (OSE) and epithelial ovarian cancers. Overexpression of Yap2 and phosphorylation-defective Yap2-5SA in immortalized OSE cells resulted in increased cell proliferation, resistance to cisplatin-induced apoptosis, faster cell migration, and anchorage-independent growth, whereas Yap knockdown resulted in increased sensitivity to cisplatin-induced apoptosis. Findings argue that the Hippo signaling pathway defines an important pathway in progression of ovarian cancer. Cancer Res; 70(21); 8517-25. ©2010 AACR.

Introduction

Epithelial ovarian cancer is the most lethal gynecologic malignancy and is the fifth most prevalent cause of cancer death in women in the United States (1). Due to the internal localization of the ovaries, lack of specific symptoms, and lack of effective screening methods, ovarian cancer usually remains undetected until it has reached an advanced stage (2). Nearly 70% of patients present with late-stage disease that has spread to other organs in the abdominal cavity, and the 5-year survival for these patients remains at only 30% (1). The current standard of care includes surgical resection of the tumor followed by treatment with platinum- and taxane-based chemotherapies (3).

An important step in the development of more targeted and personalized treatments for ovarian cancer is identification of molecules involved in its development and progression. One method for identifying such molecules is through the study of model organisms. Several laboratories have developed mouse models of ovarian cancer through targeted disruption or expression of candidate ovarian cancer tumor suppressors and oncogenes in the proposed site of origin of ovarian cancer—the ovarian surface epithelium (OSE; ref. 4). Although useful for the characterization of candidate molecules, the mammalian ovary does not lend itself to large-scale forward genetic screens that can identify new molecules.

We hypothesized that the Drosophila ovary might serve as a powerful genetic model to screen for molecules disrupted in human ovarian cancer. Mutations in basolateral junction proteins discs large, lethal giant larvae, and scribble in the fly ovary result in tumor-like phenotypes, including overproliferation, loss of cell polarity, and invasion (5–7). To identify new molecules involved in ovarian tumorigenesis, we performed a large-scale genetic modifier screen for genes that enhance the discs large ovarian tumor phenotype, and identified warts. Further analysis revealed that warts loss alone caused tumors in the Drosophila ovary (7).

Warts is a kinase that regulates organ size and tumorigenesis in many fly tissues. Warts acts in a network of tumor suppressors that encode receptor, scaffolding, and signaling molecules, collectively known as the Hippo pathway, whose crucial function is to repress oncogene Yki, a transcriptional coactivator (8). In mammals, Warts homologues Lats-1 and Lats-2 phosphorylate the Yki homologue Yap (Yes-associated protein; ref. 9) at S127, allowing 14-3-3 to bind Yap and retain
it in the cytoplasm, thus blocking the ability of Yap to coactivate transcription in the nucleus (8). Yap is located in a genomic region, 11q22, which is amplified in a variety of cancers including ovarian cancer, and Yap levels predict patient outcome in hepatocellular carcinoma (10, 11). Further, Yap overexpression in the murine liver causes massive liver overgrowth and tumorigenesis (12).

Here, we report that overexpression of human Yap induces tumorigenesis in the Drosophila ovary, suggesting that it plays a conserved role in ovarian tumorigenesis. Consistent with a role for Yap in human ovarian cancer, we found that high nuclear Yap (nYap) and low cytoplasmic phosphorylated S127-Yap (cpYap) are associated with poor survival. Further, we found that overexpression of Yap2, or a phosphorylation-resistant allele of Yap2, Yap2-5SA, in immortalized OSE (IOSE) cells resulted in increased proliferation, resistance to cisplatin-induced apoptosis, loss of contact inhibition, increased cell migration, and anchorage-independent growth. Together, these findings indicate that Yap acts as an oncogene in ovarian cancer by promoting disease progression and development of chemoresistance.

Materials and Methods

Drosophila

Yap-overexpressing flies were constructed using the FLP-out technique. Adult female y,w,hs-FLP; act>y+>Gal4, UAS-GFP/UAS-Yap-S127A flies were heat shocked at 37°C for 2 minutes and then incubated at 25°C for 3 days. Ovaries were dissected and processed as described (7).

Human tissue samples

The tissue microarray (TMA) was composed of two blocks with cores in duplicate from formalin-fixed, paraffin-embedded archival primary ovarian carcinoma samples from 70 patients (median age, 59.8; range, 22–93; Table 1). The patients had been treated at the Massachusetts General Hospital from 1989 to 2004 under an Institutional Review Board–approved protocol. H&E sections of all samples were reviewed by a certified gynecologic pathologist who selected tumor cores.

Immunohistochemistry

Normal ovary sections and the ovarian cancer TMA were analyzed by immunohistochemistry as described (13). No antigen retrieval was used for anti-Yap (1:100; H-125; Santa Cruz Biotechnology, Inc.), and 0.01 mol/L citrate buffer (pH 6.0) was used for anti–phosphorylated S127-Yap (1:50; 4911S; Cell Signaling Technology). Immunostained slides were evaluated for both nuclear and cytoplasmic Yap and pYap as described (14) by three independent scorers [T.W. (certified pathologist), C.A.H., and S.O. or S.G.] who were blinded to the data. Scores were combined using a two-third majority. Proportion scores did not vary considerably across samples and were not analyzed. Intensity scores 0 (none) and 1 (weak) were assigned to the low category, and 2 (intermediate) and 3 (strong) were assigned to the high category for both Yap and pYap.

| Table 1. Distribution of clinical characteristics of ovarian cancer patients included in this study |
|---------------------------------------------|---|---|
| Total                                      | 70 | 100.0 |
| FIGO stage                                  |   |     |
| I                                          | 23 | 32.9 |
| II                                         | 11 | 15.7 |
| III                                        | 29 | 41.4 |
| IV                                         |  7 | 10.0 |
| Tumor type                                  |   |     |
| Serous                                     | 26 | 37.1 |
| Clear cell                                 | 17 | 24.3 |
| Endometrioid                               | 17 | 24.3 |
| Mucinous                                   |  6 |  8.6 |
| Transitional                               |  4 |  5.7 |
| Tumor grade                                |   |     |
| 1                                          |  7 | 10.0 |
| 2                                          | 22 | 31.4 |
| 3                                          | 39 | 55.7 |
| Missing                                    |  2 |  2.9 |
| nYap                                       |   |     |
| Low                                        | 42 | 60.0 |
| High                                       | 25 | 35.7 |
| Missing                                    |  3 |  4.3 |
| cpYap                                      |   |     |
| Low                                        | 39 | 55.7 |
| High                                       | 28 | 40.0 |
| Missing                                    |  3 |  4.3 |
| nY/cpY category                            |   |     |
| 0 Low                                      | 22 | 31.4 |
| 1 Low Low                                  | 19 | 27.1 |
| 2 High Low                                 |  6 |  8.6 |
| 3 High Low                                 | 18 | 25.7 |
| Missing                                    |  5 |  7.1 |


Cell lines

All cell lines were grown in a 1:1 mixture of MCDB 105 medium (Sigma-Aldrich Co.) and Medium 199 (Sigma-Aldrich) supplemented with 10% fetal bovine serum (FBS), 25 μg/mL gentamicin, 10 units/mL penicillin, and 10 ng/mL streptomycin. The IOSE-80 cell line (15), which normally senesces around passage 20, was immortalized by infection with a hTERT-expressing retrovirus (Addgene plasmid 1774), followed by selection with 100 μg/mL G418 for 10 days. The resulting cell line, 80T, is able to grow for at least 90 passages. Yap knockdown lines were made by infecting 80T cells with pGIPZ lentiviruses from Open Biosystems per the manufacturer’s instructions followed by selection with 1 μg/mL puromycin for 10 days. Yap-overexpressing cell lines were
made by infecting 80T cells with pQCXIH-myc retroviruses containing Yap2 or Yap2-5SA (16), followed by selection with 200 μg/mL hygromycin for 10 days. The approximate percentage of cells in each culture expressing the indicated constructs after selection was as follows: nontargeting (90%), shYap7 (50%), shYap8 (80%), shYap9 (80%), empty vector (not measurable), Yap2 (60%), and Yap2-5SA (90%).

Sequence analysis
Whole RNA was isolated from tumors and reverse transcribed using the iScript cDNA synthesis kit (Bio-Rad). Yap fragments were PCR amplified from cDNAs. T7 or T3 sequence was added upstream of the following Yap-specific primers: Yap left forward, CCGGGCATGATCGTGCA; Yap left reverse, GCTGAAGCGGATTCATCAT; Yap right forward, TTCAAGCATGAACAGGAGAA; Yap right reverse, AGTCTGCCAGGGCTCTA. PCR products were sequenced (LoneStar Labs) using T7 and T3 primers and analyzed for mutation using Sequencher software.

Western blot analysis
Cells were harvested in radioimmunoprecipitation assay buffer (Santa Cruz Biotechnology), subjected to SDS-PAGE, and processed per antibody manufacturer’s instruction (BD Biosciences). Antibodies were used as follows: anti-Yap (1:500; H-125; Santa Cruz Biotechnology), anti–phosphorylated S127-Yap (1:500; 4911S; Cell Signaling Technology), anti–phosphorylated Lats-1 (1:200; A300-478A; Bethyl Laboratories, Inc.), anti–phosphorylated Lats-2 (1:200; ST-3D10; CycLex Corp.), and anti–actin (AC-40; 1:50,000; Sigma-Aldrich).

Immunofluorescence and imaging
Cell lines and Drosophila ovaries were stained as described (7) with anti-myc (1:500; 9E10; BD Biosciences), Alexa Fluor 647–conjugated phalloidin (1:100; Invitrogen), and propidium iodide. Tissues were visualized using a Zeiss LSM confocal microscope, and images were minimally adjusted for brightness and contrast using the Zeiss LSM510 Image Browser software.

Cell proliferation assays
For the cell count assay, 10,000 cells were plated in triplicate in 12-well plates and counted on days 1 and 6 (before confluence) using a Beckman Coulter Z1 Particle Counter. To establish a mitotic index, 10,000 cells were plated on coverslips, grown for 4 days, and stained with propidium iodide. Twenty images were captured per genotype, and the mitotic index (number of nuclei with condensed chromosomes divided by total number of nuclei) was scored.

Apoptosis assay
Cells were incubated in medium containing 30 μmol/L cisplatin (400-040-M050; Alexis Biochemicals) for 48 hours. Floating and adherent cells were harvested for Western blot analysis.

Scratch assay
Cells (2.5 × 10^6) were plated in T25 flasks with medium containing 10 μg/mL mitomycin C to block proliferation. Twelve hours later, cells were scratched using a 200 μL pipette and medium was replaced. Images of 10 scratches per cell line were captured after 30-minute recovery and at the same location 10 hours later. Scratch areas were measured using Zeiss AxioVision Software 4.6.

Soft agar assay
Cells (5,000) were plated in complete medium plus 0.5% agar in six-well plates in triplicate. Medium was replaced every 3 days. After 14 days, cells were stained with 2 mL of 0.5 mg/mL MTT for 2 hours. Visible colonies were counted.

Statistical analysis
For TMA data, clinical and immunohistochemistry variables were summarized descriptively (Table 1). For the 65 subjects with complete immunohistochemical and outcome data, disease-specific survival, truncated at 5 years, was estimated by the Kaplan-Meier method and compared across groups (see below) using the log-rank test. Patients that survived, dropped out of the study, or died for reasons unrelated to cancer were censored at the lesser of the last follow-up time or 5 years. The contribution of dichotomized nYap (low = 0, 1 versus high = 2, 3), dichotomized cpYap (low = 0, 1 versus high = 2, 3), or their combined dichotomized nY/cpY category (3 versus 0, 1, 2), independent of other clinicopathologic variables, was analyzed by stepwise Cox proportional hazards regression modeling. The following clinicopathologic variables were considered (categorized as indicated): stage (1, 2, 3, 4 treated as a single “continuous” variable because univariate analysis indicated that this was a reasonable representation), dichotomized grade [high = 3 versus other including ungraded (n = 2)], and dichotomized histology (serous versus other).

Cell culture experiments were done at least in triplicate and repeated at least three times. Western blot and immunofluorescence experiments were repeated at least three times. Student’s paired t test was used to compare each measured value with control. P values of <0.05 were considered significant.

Results
Human Yap-S127A induces tumorigenesis in the Drosophila ovary
Loss-of-function clones of warts in the fly ovarian follicular epithelium results in tumor formation (7). We thus tested if the key Warts target, Yki, also induces tumors. Using the FLP-out technique, we overexpressed wild-type Yki and phosphorylation-resistant Yki-S168A in the Drosophila ovarian follicular epithelium and found that Yki-S168A, but not wild-type Yki, induced tumorigenesis (Fig. 1; data not shown). To test if the human homologue of Yki, Yap, might play a conserved role in ovarian tumorigenesis, we overexpressed wild-type Yap and a phosphorylation-resistant allele of Yap, Yap-S127A, in the Drosophila ovarian follicular
epithelium. Similar to Yki, expression of wild-type Yap had no effect, whereas expression of Yap-S127A resulted in overproliferation and loss of epithelial architecture beginning at mid-oogenesis (data not shown; Fig. 1). We conclude that the oncogenic capacity of Yki in the fly ovary is conserved in human Yap.

Yap does not seem to have activating mutations in ovarian cancer

Because activating mutations in Yap are able to induce tumors in the fly ovary, we reasoned that Yap might be activated by mutation in ovarian cancer. Mutation of any of the five Lats consensus binding/phosphorylation sites in Yap (16) could result in constitutive activation of Yap. We sequenced these sites in cDNAs synthesized from whole-cell RNA from 10 ovarian cancer cell lines, 2 IOSE cell lines, and 17 ovarian tumors, but did not detect any nonsynonymous mutations. We conclude that Yap is not frequently mutated at any of the five Lats consensus binding/phosphorylation sites in ovarian cancer. We cannot rule out that Yap might be activated by mutation at low frequency and/or at other sites in ovarian cancer.

Yap is not overexpressed or underphosphorylated at S127 in ovarian cancer cell lines

Others have shown that Yap is overexpressed in hepatocellular carcinoma (11). To test if Yap is overexpressed in ovarian cancer, we performed Western blot analysis on 10 ovarian cancer cell lines and 2 IOSE cell lines (Supplementary Fig. S1A). Using an antibody raised against a fragment of Yap1 that is contained in Yap2 and Yap2L, one prominent 65-kDa band corresponding to Yap2 (see below) was evident by Western blot analysis. Yap2 was expressed in all cell lines, and Yap2 levels varied to a similar extent in ovarian cancer cells and control cell lines. Because Yap is inhibited by phosphorylation at S127 by Lats-1 or Lats-2 kinases (16), we also asked if Lats kinases are expressed and if Yap is phosphorylated in ovarian cancer cell lines (Supplementary Fig. S1A). Lats-1 and Lats-2 were expressed in all cell lines and pYap levels varied to a similar extent in ovarian cancer and control cell lines (Supplementary Fig. S1A). We conclude that Yap is not overexpressed and that Yap phosphorylation at S127 is not grossly misregulated in ovarian cancer cell lines.

Subcellular levels of Yap and pYap correlate with ovarian cancer survival

To further explore the possibility that Yap is misregulated in ovarian cancer, we reasoned that because cytoplasmic retention is the primary mechanism controlling Yap nuclear accumulation (8), Yap subcellular distribution might correlate with patient survival in ovarian cancer. After verifying the specificity of our Yap and pYap antibodies (Supplementary Fig. S1B), we established the normal expression pattern of Yap and pYap by staining normal OSE (NOSE). Similar to a previous report, Yap staining was low or undetectable in most (five of seven) samples (17). When Yap was expressed in the OSE, it localized predominantly to the nucleus and pYap localized predominantly to the cytoplasm (Fig. 2A).

To determine if Yap distribution correlates with patient survival in ovarian cancer, Yap and pYap localization and levels were evaluated in 70 tumors on an ovarian cancer TMA, which contained a mixture of serous, clear cell, endometrioid, mucinous, and transitional carcinomas (Table 1). Kaplan-Meier estimation and comparison of disease-specific survival found high nYap staining intensity ($P = 0.002$) to be associated and low cytoplasmic pYap (cpYap) staining intensity ($P = 0.07$) to be marginally associated with poor patient outcome (Fig. 2B). In contrast, cytoplasmic Yap staining intensity and nuclear pYap staining intensity were not associated. Although nYap staining intensity remained a significant independent marker for poor patient survival [$P = 0.0048$; hazard ratio (HR), 3.3; 95% confidence interval (CI), 1.03–10.9] after considering other clinical factors (data not shown), we sought to determine if the combination of nYap
and cpYap staining intensities showed an even stronger association with poor patient survival. We sorted each tumor into one of four categories based on the combination of nYap and cpYap staining intensities (Table 1). Survival in patients with both high nYap and low cpYap (nY/cpY category 3) was significantly worse than the other categories, which were combined because they were indistinguishable from each other on univariate survival analysis (Fig. 2B). On multivariate Cox regression analysis that considered stage, high grade, serous histology, dichotomized nYap score, dichotomized cpYap score, and the dichotomized nY/cpY category (3 versus other), only stage ($P < 0.001; \text{HR}, 7.0; 95\% \text{ CI}, 3.0–16.5$) and nY/cpY category ($P = 0.002; \text{HR}, 7.8; 95\% \text{ CI}, 2.1–28.9$) were significant. We conclude that the combination of high nYap and low cpYap is a strong independent predictor of disease-specific survival for ovarian cancer.

**Yap overexpression promotes proliferation and resistance to apoptosis**

Correlations between Yap staining and poor patient survival do not distinguish whether Yap merely correlates with ovarian cancer outcome or if Yap is an active driver of the disease. To determine if Yap is an active driver of ovarian cancer progression, we used an IOSE cell line, 80T, as an *in vitro* model. cDNA sequencing (above) indicated that Yap2 was the predominantly expressed Yap isoform in NOSE, IOSE, and ovarian cancer cell lines. Yap1 and Yap2L transcripts were also detected but at relatively low levels.

Therefore, to obtain IOSE cells with high nYap, as observed in ovarian tumors, we overexpressed Yap2, which would be expected to increase nYap by mass action, and Yap2-5SA, which is resistant to cytoplasmic retention due to mutation of all five Lats phosphorylation sites (Fig. 3A; ref. 16). Additionally, we knocked down Yap with short hairpin RNAs (shRNA; Fig. 3A). Consistent with Yap2 being the predominantly expressed isoform in 80T cells, overexpressed Yap2, which is myc-tagged, ran only slightly higher than the endogenously expressed isoform (Fig. 3A). We also determined the localization of Yap in Yap2- and Yap2-5SA-overexpressing cell lines (Fig. 3A). Although most overexpressed Yap localizes in the cytoplasm, there is more nYap in cells overexpressing Yap2 and Yap2-5SA compared with control cells (Fig. 3A; Supplementary Fig. S1B).

![Figure 2](image_url)
To determine if Yap regulates cell proliferation, we compared cell number in Yap knockdown, overexpression, and control cells after 6 days in culture. 80T cells overexpressing Yap2 or Yap2-5SA contained significantly more cells than control, whereas cells knocked down for Yap showed no significant difference (Fig. 3B). The increase in cell number could be due to increased proliferation, decreased cell death, or both. To determine if Yap2- and Yap2-5SA–overexpressing
cells had increased proliferation, we established their mitotic index (Fig. 3B). Yap2 or Yap2-5SA overexpression resulted in significantly higher mitotic index compared with control, suggesting that these cultures were more proliferative. We asked if this effect might be mediated by the epidermal growth factor (EGF) family ligand amphiregulin, a protein implicated in ovarian cancer, and that acts downstream of Yap in breast cells to promote proliferation (2, 18). Amphiregulin levels were unchanged in 80T cells overexpressing Yap2 or Yap2-5SA by both Western blot and immunohistochemical analysis (data not shown).

To determine if Yap expression decreases cell death, we challenged with cisplatin, one of the most commonly used ovarian cancer chemotherapeutic agents (3). After 48 hours of treatment, Yap2- or Yap2-5SA–overexpressing cells remained adherent to the culture dish, whereas control and shYap cells rounded up and detached (Fig. 3C), suggesting that Yap2 overexpression protects from apoptosis. To test

---

**Figure 4.** Yap overexpression reduces contact inhibition and promotes wound closure and anchorage-independent growth. A, micrographs of confluent cultures stained for DNA to reveal cell density. Greater fluorescence intensity reveals multilayering of cells. B, representative bright-field micrographs (left) of control and Yap2-5SA cells 0.5 and 10 h after wounding. Quantification of wound closure (right) after 10 h. C, representative micrograph of cell colonies visualized with MTT (left) after 14 d of growth in soft agar. Right, quantification of the number of colonies per well. *, P < 0.05; ***, P < 0.001.
if Yap2 or Yap2-5SA cells have decreased apoptosis, we performed Western blot analysis of initiator and effector caspases, caspase-8 and caspase-3, respectively (19). Yap knockdown resulted in higher levels of both cleaved caspases, whereas overexpression of Yap2 and Yap2-5SA showed decreased levels of cleaved caspase-8, increased levels of full-length caspase-8, and a small, but reproducible, decrease in cleaved caspase-3 (Fig. 3C). We conclude that overexpression of Yap2 or Yap2-5SA results in increased proliferation and decreased cisplatin-induced apoptosis, whereas Yap knockdown results in increased cisplatin-induced apoptosis.

**Yap overexpression reduces contact inhibition and promotes movement and anchorage-independent growth**

In addition to increased growth, aggressive tumor cells undergo epithelial to mesenchymal transition (EMT), lose contact inhibition, develop increased motility, and develop anchorage-independent growth. We investigated these processes in Yap-overexpressing and knockdown cells. We noticed that when Yap2- and Yap2-5SA-overexpressing cells reached full confluence, cell density was higher (Fig. 4A), indicating loss of contact inhibition. We also found that overexpression of Yap2-5SA, but not overexpression of Yap2 or Yap knockdown, resulted in significantly faster wound closure (Fig. 4B). Further, cells overexpressing Yap2 and Yap2-5SA formed colonies in soft agar (Fig. 4C), whereas control cells and cells with diminished Yap were unable to grow. We conclude that Yap promotes loss of contact inhibition, cell migration, and growth in soft agar.

EMT is often associated with loss of contact inhibition, increased cell migration, and increased growth in soft agar, and Yap has been shown to induce EMT in human mammary epithelial cells (20). However, 80T cells already appear mesenchymal (Figs. 3A and C and 4B), express mesenchymal markers (fibronectin and vimentin), and do not express epithelial markers (E-cadherin, occludin, or β-catenin; data not shown). Yap knockdown and Yap2 or Yap2-5SA overexpression did not alter the expression of these markers (data not shown). We conclude that Yap can promote loss of contact inhibition, cell migration, and growth in soft agar independent of EMT.

**Discussion**

We found that, similar to Yki, phosphorylation-resistant human Yap is able to induce ovarian tumors when expressed in the *Drosophila* ovary, suggesting that the ability of Yap and Yki to induce ovarian tumorigenesis is conserved. Although we found no evidence of activating mutations in Yap in ovarian cancers, or for Yap overexpression in cell lines, we found that subcellular levels of Yap and pYap correlate and tend to associate, respectively, with survival of ovarian cancer patients. Consistent with a role for Yap in ovarian cancer progression, we find that overexpression of Yap2 and phosphorylation-defective Yap2-5SA in 80T cells resulted in several phenotypes associated with cancer, including increased proliferation, resistance to cisplatin-induced apoptosis, faster cell migration, and anchorage-independent growth, whereas knockdown of Yap in these cells resulted in increased sensitivity to cisplatin-induced apoptosis.

Paradoxically, Yap has been shown to act as both a tumor suppressor and an oncogene in breast cancer (20, 21). However, neither of these studies attempted to correlate Yap expression with patient outcome, which would help resolve this controversy. Three lines of evidence refute a role for Yap as a tumor suppressor in ovarian cancer. First, low nYap expression in ovarian tumors correlated with better disease-specific survival. Second, Yap was not lost or dramatically downregulated in 10 ovarian cancer cell lines. Third, Yap knockdown in 80T cells did not result in phenotypes associated with cancer. In fact, Yap knockdown cells were more sensitive to cisplatin-induced apoptosis than control cells (Fig. 3C).

Although the sample size is modest and should be interpreted cautiously, Yap seems to be a powerful prognostic marker of poor survival in ovarian cancer. Cox regression analysis of the nY/cpY category (3 versus 0, 1, 2) revealed an exceptionally high HR of 7.7 (comparable with the HR of 7.0 for stage), indicating that, in our data set, patients with both high nYap and low cpYap are at nearly eight times greater risk of death from the disease than other patients. This HR is substantially higher than the HR for nYap staining alone (HR, 3.3). There could be two explanations for this finding. First, immunohistochemical studies of archival tumor samples can be confounded by both systematic and random errors such as intersample and intrasample heterogeneity and differences in the age, fixation, processing, staining, and scoring of tumor samples. Therefore, two independent measures of the same marker would be expected to reduce error. Second, the nY/cpY category might reflect the activity of Yap in the tumor. Yap is phosphorylated at S127 by Lats kinases and retained in the cytoplasm by 14-3-3 (8). When Yap is localized in the nucleus, it is likely transcriptionally active, and thus, intense nYap staining suggests high Yap activity. In contrast, when Yap is phosphorylated and in the cytoplasm, Yap is presumably transcriptionally inactive, and thus, intense cpYap staining suggests low Yap activity. Thus, tumors in nY/cpY category 3, which have high levels of nYap and low levels of cpYap, might be expected to have the highest Yap activity. Analysis of the levels of Yap target genes in each nY/cpY category might shed light on these two possibilities.

An important question that remains is the mechanism of Yap misregulation in ovarian cancer. We found no evidence for Yap protein amplification or for Yap-activating mutations. Further, pYap staining was detectable in 63 of 70 ovarian tumors and in all ovarian cancer cell lines (Supplementary Fig. S1A), indicating that increased nYap does not likely result from complete loss of phosphorylation. A variety of mechanisms have been described in *Drosophila* that alter Yki levels and subcellular localization (8), providing several possible mechanisms by which nYap levels may increase in human ovarian cancer. Elucidation of these mechanisms will likely provide insight for therapeutic intervention targeting Yap.

Our results support the notion that Yap might be an excellent therapeutic target for the treatment of ovarian cancer. Although our sample size is modest and our analysis needs
to be confirmed in a larger patient population, Yap distribution seems to be a very strong predictor of survival from ovarian cancer. Even if further analysis reveals that the HR for nY/cpY category 3 is at the low end of our 95% CI (2.1–28.9), this would be on par with EGF and Her-2/neu, which are currently targeted in clinical trials for ovarian cancer treatments (22, 23). Further, Yap activation results in several cancer-associated phenotypes, whereas reduction of Yap resulted only in increased sensitivity to chemotherapy, indicating that therapies targeting Yap could affect multiple cancer processes with minimal deleterious effects.

The Drosophila ovarian follicular epithelium and human OSE are female-specific tissues that share many important properties including mesodermal origin, monolayer cuboidal epithelial organization, hormone dependency, and the ability to undergo dynamic remodeling (7, 24–26). The results presented here support the notion that the Drosophila follicular epithelium is a useful tool for the discovery of genes crucial to the pathogenesis of ovarian cancer.

**Disclosure of Potential Conflicts of Interest**

No potential conflicts of interest were disclosed.

**Acknowledgments**

We thank George Halder, Kun-Liang Guan, Marius Sudol, Craig Allred, Michael Ittmann, Wendong Yu, Jianghua Wang, Yi Cai, Patricia Castro, and Gordon Mills for reagents and advice, and anonymous reviewers for helpful suggestions.

**Grant Support**

NIGMS grant 2R01 CA087759-06A2 and Mary Kay Ash grant 038-03 (S. Goode) and NIH grant R01 CA103924 (S. Orsulic). C.A. Hall was supported by NIH training grant T32 GM008307.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 04/09/2010; revised 08/11/2010; accepted 08/25/2010; published OnlineFirst 10/14/2010.

**References**

Hippo Pathway Effector Yap Is an Ovarian Cancer Oncogene

Chad A. Hall, Runsheng Wang, Jiangyong Miao, et al.

Cancer Res 2010;70:8517-8525. Published OnlineFirst October 14, 2010.

Updated version
Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-10-1242

Supplementary Material
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2010/10/14/0008-5472.CAN-10-1242.DC1

Cited articles
This article cites 26 articles, 5 of which you can access for free at:
http://cancerres.aacrjournals.org/content/70/21/8517.full#ref-list-1

Citing articles
This article has been cited by 19 HighWire-hosted articles. Access the articles at:
http://cancerres.aacrjournals.org/content/70/21/8517.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.